Zogenix announces new efficacy data from long-term study of low-dose fenfluramine
Zogenix announced new data demonstrating sustained efficacy and tolerability for patients treated with low-dose fenfluramine as an adjunctive therapy for Dravet syndrome. Zogenix intends to initiate Phase 3 clinical studies for ZX008 during the second half of 2015. May 27, 2015